Objective: A comprehensive knowledge about BPH and hypertension is needed to reduce morbidity and mortality in patients with decreased kidney function due to the two diseases. Material & Methods: This research used the observational analytics method with cross-sectional design. This research used secondary data from medical records of BPH patients in Bina Sehat Hospital and Paru Hospital from January 1st to December 1st 2019. Results: Comparative serum creatinine test results in hypertensive BPH patients with non-hypertensive BPH patients using the Mann Whitney test, obtained p= 0.000. Based on these results it can be concluded that there are significant differences in serum creatinine between hypertensive BPH patients and non-hypertensive BPH patients. Correlation test results using the Spearman test between serum creatinine with blood pressure systole and diastole all samples obtained each p= 0.000 r= 0.399 for systolic blood pressure and p= 0.000 r= 0.337 for diastole blood pressure. Based on these results it can be concluded that there is a significant correlation between serum creatinine with systolic and diastolic blood pressure of the patient. Conclusion: Hypertension will worsen the kidney function decline in BPH patients seen from an increase in serum creatinine.
BPH, hypertension, kidney function, creatinine, blood pressure
Robert, G., Descazeaud A., Nicolaiew, N., Terry, S., Sirab, N., Vacherot, F., Maille, P., Allory, Y., de la Taille, A. Inflammation in benign prostatic hyperplasia: a 282 patient’s immunohistochemical analysis. The Prostate. 2009; 69(16): 1774-1780.
Kocjancic, E. Benign Prostatic Hyperplasia (BPH). Encyclopedia of Reproduction. 2018; 4(2): 467-72.
Lee, S. H., Park, K. K., Mah, S. Y., Chung, B. H. Effect of alfa-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concominant hypertension. Prostate Cancer and Prostatic Disease. 2010; 13(4): 333-337
Mathur, R. P., Nayak, S., Sivaramakrishnan, R., Jain, V. Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia. Journal of Association of Physicians of India. 2014; 62(9): 40-4.
Lim, K. B. Epidemiology of Clinical Benign Prostatic Hyperplasia. Asian Journal of Urology. 2017; 4(3): 148-151
Breyer, B. and Sarma, V. Hyperglycemia and Insulin Resistance and the Risk of BPH/LUTS: an Update on Recent Literature. Current Urology Report. 2014; 15(462): 1-6.
Kunz, R. et al. Meta Analysis: Effect of Monotherapy and Combination Therapy with Inhibitor of Renin Angiotensin System on Proteinuria in Renal Disease. Annals of Internal Medicine. 2008; 143: 30.
Kaplan, M.N. Kaplan’s Clinical Hypertension 10th Edition. Dallas: Lippincott Williams & Wilkins. 2010.
Coresh, J., Wei, L., McQuillan, G. Pravalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States. Arch Intern Med. 2001. 161(9):1207-1216
Speakman, M. J., Cheng, X. Management of the Complication of BPH. Musgrove Park Hospital. 2014; 30(2): 208-213.
Buffet, L., Richetti, C. Chronic Kidney Disease and Hypertension: A Destructive Combination. US Pharmacist. 2012; 37(6): 26-29.
Cellek, S., Cameron, N. E., Cotter, M. A., Fry, C. H., Ilo, D. Microvascular Dysfunction and Efficacy of PDE5 Inhibitors in BPH-LUTS. National Reviews of Urology. 2014; 11: 231-241.
Tousoulis, D., Kampoli A. M., Stefanadis, C. The Role of Nitric Oxide on Endothelial Function. Current Vascular Pharmacology. 2012; 10: 4-18.
Peixoto, C. A., Gomes, F. O. The Role of Phosphodiesterase-5 inhibitors in Prostatic Inflammation: a Review. Journal of Inflammation. 2015; 12: 54.
Michel, M.C., Heerman, U., Schumacer, H., Mehlburger, L., Goepel, M. Association of Hypertension with Symptoms of Benign Prostatic Hyperplasia. The Journal of Urology. 2004; 172: 1390-1393.